Balaton Aktiengesellschaft Deutsche - 16 Sep 2025 Form 3 Insider Report for Biofrontera Inc. (BFRI)

Reporting relationship: 10%+ Owner
Issuer ticker: BFRI
Reported as of: 16 Sep 2025
Net transaction value: $0
SEC form: 3
Accepted by SEC: 26 Sep 2025, 16:49:22 UTC
Source filing: View source filing
Reporting owner signature: By: /s/ Martin Flick, attorney in fact for Deutsche Balaton Aktiengesellschaft

Key filing fact

Balaton Aktiengesellschaft Deutsche filed Form 3 for Biofrontera Inc. (BFRI) on 26 Sep 2025.

Key facts

This page summarizes Balaton Aktiengesellschaft Deutsche's Form 3 filing for Biofrontera Inc. (BFRI).
0 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 26 Sep 2025, 16:49.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0001571071 Primary reporting owner

DEUTSCHE BALATON AKTIENGESELLSCHAFT

Relationship: 10%+ Owner
Address: ZIEGELHAUSER LANDSTRASSE 3, HEIDELBERG, GERMANY
Signature: By: /s/ Martin Flick, attorney in fact for Deutsche Balaton Aktiengesellschaft
Signature date: 26 Sep 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BFRI holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 58,884
Date: 16 Sep 2025
Ownership: Direct

BFRI holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 400,000
Date: 16 Sep 2025
Ownership: By Biofrontera AG
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BFRI holding Derivative

Series D Convertible Preferred Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 16 Sep 2025
Ownership: By Biofrontera AG
Underlying class: Common Stock
Underlying amount: 4,831,172
Exercise price: $0.6249
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The reported shares are held directly by Biofrontera AG. The Reporting Person and its affiliates collectively hold approximately 62.2% of the outstanding voting stock of Biofrontera AG and therefore may be deemed to beneficially own the shares owned by Biofrontera AG. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of its indirect pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

Footnote F2

The convertible preferred stock is convertible at any time at the holder's option, subject to a limitation that prevents the holder and its affiliates from beneficially owning more than 19.99% of the outstanding common stock upon conversion. The preferred stock has no expiration date.